Maxcyte, INC Form 4 insider transactions

MaxCyte CFO Parmeet Ahuja was granted 187,500 restricted stock units as part of an equity compensation arrangement.

Maxcyte, Inc. reports that Chief Financial Officer Parmeet Ahuja acquired 375,000 employee stock options.

MAXCYTE, INC. President and CEO, Maher Masoud, acquired 300,000 restricted stock units and 600,000 employee stock options, aligning executive incentives with long-term company performance.

MaxCyte's Chief Financial Officer, Douglas J. Swirsky, sold 10,142 shares of common stock to cover tax withholding obligations related to RSU vesting.

MAXCYTE Director Rekha Hemrajani sold 10,684 shares of common stock for a weighted average price of $2.0945 per share, pursuant to a pre-arranged 10b5-1 trading plan.

MAXCYTE's Chief Financial Officer, Douglas J Swirsky, acquired 50,000 shares of common stock at $1.29 per share.

MAXCYTE, Inc.'s President and CEO, Masoud Maher, acquired 75,000 shares of common stock at an average price of $1.3722.

MAXCYTE, Inc. Director Stanley C. Erck purchased 100,000 shares of common stock for approximately $137,220.

MAXCYTE, Inc. Director Richard Douglas acquired 80,000 shares of common stock for approximately $111,040.

MAXCYTE, Inc. Director William W. Brooke acquired 50,000 shares of common stock at $1.29 per share, increasing his direct beneficial ownership to 150,879 shares.

MaxCyte, Inc. Director John Joseph Johnston was granted 29,210 restricted stock units and 50,790 stock options as part of his annual compensation, increasing his beneficial ownership.

MAXCYTE, Inc. Director Rekha Hemrajani has acquired 29,210 restricted stock units and 50,790 stock options as part of an annual equity grant, aligning her interests with shareholders.

MaxCyte, Inc. Director Stanley C. Erck reported the acquisition of 29,210 restricted stock units and 50,790 stock options as part of his annual compensation.

MaxCyte, Inc. Director Richard Douglas was granted 29,210 restricted stock units and 50,790 stock options as part of his annual compensation, as disclosed in a recent SEC Form 4 filing.

MAXCYTE, Inc. Director Cynthia Collins was granted 29,210 Restricted Stock Units and 50,790 stock options as part of her annual compensation, according to a recent SEC Form 4 filing.

MaxCyte, Inc. Director William W. Brooke was granted 29,210 restricted stock units and 50,790 stock options as part of his annual compensation, vesting on June 18, 2026.

MaxCyte, Inc. Director Patrick J. Balthrop was granted 29,210 restricted stock units and 50,790 stock options, effective June 18, 2025, as part of the company's non-employee director equity policy.

MaxCyte, Inc. Director Yasir B. Al-Wakeel was granted 29,210 Restricted Stock Units and 50,790 stock options as part of the company's annual equity compensation policy for non-employee directors.

Ali Soleymannezhad, Chief Commercial Officer of MaxCyte, Inc., sold 1,211 shares of common stock on March 18, 2025, to cover tax withholding obligations related to vested restricted stock units.

David Sandoval, General Counsel of MaxCyte, Inc., reports the sale of 353 shares of common stock to cover tax withholding obligations upon the vesting of restricted stock units.

Douglas Swirsky, CFO of MaxCyte, Inc., reported the sale of 6,939 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Chief Commercial Officer Ali Soleymannezhad reports acquisition of restricted stock units and stock options in MaxCyte, Inc.

David I. Sandoval, General Counsel of MaxCyte, Inc., reports the acquisition of stock options and restricted stock units.

Douglas Swirsky, CFO of MaxCyte, Inc., reports the acquisition of restricted stock units and stock options.

MaxCyte's CEO, Maher Masoud, was granted stock options for 347,500 shares on March 14, 2025.

Director John Johnston exercised stock options and sold shares of MaxCyte, Inc. under a pre-arranged Rule 10b5-1 trading plan.

David I. Sandoval, General Counsel of MaxCyte, Inc., sold shares of common stock to cover tax withholding obligations upon the vesting of restricted stock units.

Director John Johnston exercised stock options and sold shares of MaxCyte, Inc. (MXCT) on December 26, 2024, under a pre-arranged Rule 10b5-1 trading plan.

MaxCyte Inc. executive John Joseph Johnston executed multiple stock transactions, including sales and option exercises, under a pre-arranged Rule 10b5-1 trading plan.

Director Stanley C. Erck exercised stock options and sold shares of MaxCyte, Inc. under a pre-arranged Rule 10b5-1 trading plan.